Clinical Trials Browser

OTHER × toripalimab × Breast × Clear all

NCT07457359 2026-03-09

NEOTRIO-2

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT07383818 2026-02-03

Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)

Phase 2 Recruiting

Breast Neoplasms

NCT07378306 2026-01-30

FACT-TN

Phase 2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06682195 2026-01-14

Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT07244874 2025-11-24

Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC

Phase 2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT07040644 2025-09-08

A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC

Phase 2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT06371274 2025-08-12

A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.

Phase NA Recruiting

Triple Negative Breast Neoplasms

NCT06611813 2025-08-12

Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)

Phase 2 Recruiting

Breast Neoplasms

NCT07101614 2025-08-03

A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer (TNBC).

Phase 2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT06914440 2025-07-15

Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT06991790 2025-05-28

Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration

Triple Negative Breast Neoplasms

NCT06977893 2025-05-18

Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)

Phase 3 Recruiting

Breast Neoplasms

NCT06964906 2025-05-11

NeoHunter

Phase 2 Recruiting

Breast Neoplasms

NCT06878625 2025-03-25

A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT06618014 2025-01-16

NeoTOP

Phase 2 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04418154 2024-05-21

NeoTENNIS

Phase 2 Active not recruiting

Triple Negative Breast Neoplasms

NCT05749575 2023-03-01

Chidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast Cancer.

Phase 2 Unknown

Breast Neoplasms

NCT05491694 2022-08-08

HIFU

Phase 2 Unknown

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04389073 2022-02-25

Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine

Phase 2 Unknown

Breast Neoplasms

NCT04234620 2020-01-21

Intensive Medicines Monitoring Study of Toripalimab Monoclonal Injection (Tuoyi) .

BreastDermatologic

Breast Neoplasms, Melanoma